Beigene Ltd (NASDAQ:BGNE)

159.26
Delayed Data
As of May 22
 -5.34 / -3.24%
Today’s Change
113.01
Today|||52-Week Range
210.35
-3.92%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$12.3B

Company Description

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Contact Information

BeiGene Ltd.
Zhongguancun Life Science Park
Beijing Beijing 102206
P:861058958000
Investor Relations:

Employees

Shareholders

Other institutional39.54%
Mutual fund holders25.65%
Individual stakeholders22.30%

Top Executives

There are no executives to display.